Patents by Inventor Michael Niederweis
Michael Niederweis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124928Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: ApplicationFiled: April 24, 2023Publication date: April 18, 2024Applicants: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Patent number: 11858966Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.Type: GrantFiled: February 17, 2022Date of Patent: January 2, 2024Assignee: THE UAB RESEARCH FOUNDATIONInventors: Michael Niederweis, Mikhail Pavlenok
-
Patent number: 11634764Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: GrantFiled: December 14, 2020Date of Patent: April 25, 2023Assignees: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Publication number: 20220169683Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.Type: ApplicationFiled: February 17, 2022Publication date: June 2, 2022Applicant: THE UAB RESEARCH FOUNDATIONInventors: Michael Niederweis, Mikhail Pavlenok
-
Patent number: 11292817Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.Type: GrantFiled: August 19, 2020Date of Patent: April 5, 2022Assignee: THE UAB RESEARCH FOUNDATIONInventors: Michael Niederweis, Mikhail Pavlenok
-
Publication number: 20210189480Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: ApplicationFiled: December 14, 2020Publication date: June 24, 2021Applicants: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Publication number: 20210040163Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.Type: ApplicationFiled: August 19, 2020Publication date: February 11, 2021Applicant: THE UAB RESEARCH FOUNDATIONInventors: Michael Niederweis, Mikhail Pavlenok
-
Patent number: 10870883Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: GrantFiled: June 1, 2018Date of Patent: December 22, 2020Assignees: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Patent number: 10781237Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.Type: GrantFiled: April 16, 2015Date of Patent: September 22, 2020Assignee: THE UAB RESEARCH FOUNDATIONInventors: Michael Niederweis, Mikhail Pavlenok
-
Publication number: 20190062825Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: ApplicationFiled: June 1, 2018Publication date: February 28, 2019Applicants: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Patent number: 10017550Abstract: Provided herein are isolated polypeptides comprising the amino-terminal domain of Mycobacterium tuberculosis porin A (MtpA), wherein the polypeptide is a porin monomer. Also provided are isolated polypeptides comprising the carboxy-terminal domain of Mycobacterium tuberculosis porin A, wherein the polypeptide is a toxin. Also provided are methods of treating or preventing a Mycobacterium tuberculosis (Mtb) infection in a subject with or at risk of developing a Mtb infection. Further provided are chimeric porin polypeptides comprising a first polypeptide comprising an amino-terminal domain of Mycobacterium tuberculosis porin and a second polypeptide comprising an antigen and the use the chimeric porin polypeptides in methods of eliciting an immune response in a subject.Type: GrantFiled: August 30, 2012Date of Patent: July 10, 2018Assignee: The UAB Research FoundationInventors: Michael Niederweis, Olga Danilchanka
-
Patent number: 9988679Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: GrantFiled: April 14, 2017Date of Patent: June 5, 2018Assignees: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Publication number: 20170218443Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: ApplicationFiled: April 14, 2017Publication date: August 3, 2017Applicants: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Patent number: 9624275Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: GrantFiled: June 27, 2014Date of Patent: April 18, 2017Assignees: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Publication number: 20170029475Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.Type: ApplicationFiled: April 16, 2015Publication date: February 2, 2017Applicant: The UAB Research FoundationInventors: Michael Niederweis, Mikhail Pavlenok
-
Patent number: 9540422Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: GrantFiled: January 12, 2016Date of Patent: January 10, 2017Assignees: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Patent number: 9534024Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: GrantFiled: March 17, 2014Date of Patent: January 3, 2017Assignees: THE UAB RESEARCH FOUNDATION, UNIVERSITY OF WASHINGTONInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Publication number: 20160137703Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: ApplicationFiled: January 12, 2016Publication date: May 19, 2016Applicants: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Patent number: 9170230Abstract: Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.Type: GrantFiled: March 17, 2014Date of Patent: October 27, 2015Assignees: University of Washington, The UAB Research FoundationInventors: Jens H. Gundlach, Michael Niederweis, Thomas Z. Butler, Mikhail Pavlenok, Mark A. Troll, Suja Sukumaran
-
Publication number: 20150105333Abstract: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-?B activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-?B activity without a second delayed increase in NF-?B activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.Type: ApplicationFiled: October 17, 2014Publication date: April 16, 2015Inventors: Olaf Kutsch, Michael Niederweis, Frank Wolschendorf, Alexandra Duverger, Frederic Wagner